Wellcome Leap has awarded Algorithmiq a 2 million prize as the first successful outcome of its 50 million Q4Bio program, recognizing a quantum application demonstrated on a computer exceeding 50 qubits and achieving a program depth of 10³, to 10⁴. The initiative, launched in 2023, focused on problems beyond the reach of existing computers to determine if quantum computing could deliver practical benefits for biology and healthcare before substantial investment. Algorithmiq’s multidisciplinary team, collaborating with IBM and Cleveland Clinic, developed a quantum-classical workflow to calculate excited-state properties of a drug used in photodynamic cancer therapy, identifying a path toward scalable quantum advantage. “When we started the Wellcome Leap program, it wasn’t clear exactly how or where quantum computing could meaningfully impact biology,” said Shihan Sajeed, Program Director for Q4Bio. “Q4Bio was designed to create new solutions that would answer that question within real biological and hardware constraints.”
50 Million Q4Bio Program Launched to Seek Quantum Advantage
Wellcome Leap invested 50 million in the Q4Bio program, allocating 40 million to research funding and reserving up to 10 million for prizes; this financial commitment signaled a determination to establish quantum computing’s practical value in healthcare before definitive results emerged. Over a 30-month period, Q4Bio assembled collaborative teams of quantum software and hardware experts alongside biologists, focusing on high-impact use cases and co-developing solutions. This accomplishment represents a significant technical milestone, overcoming a hurdle many considered formidable. The program’s impact extends beyond prize money, however.
Algorithmiq Wins 2 Million Prize for Photosensitizer Drug Calculation
The pursuit of practical quantum computing applications in healthcare received a boost as Algorithmiq secured a 2 million prize within Wellcome Leap’s Quantum for Bio program; this award acknowledges a step toward realizing quantum advantage in biology. Launched in 2023, the program aimed to move beyond theoretical promise and demonstrate tangible benefits for human health, assembling collaborative teams of experts in quantum computing and biology. The multidisciplinary team, partnering with IBM for hardware and the Cleveland Clinic for biological expertise, developed an end-to-end quantum-classical workflow. The program’s success isn’t solely defined by the prize money, but by the evidence-based understanding of quantum computing’s potential within the constraints of current technology, establishing a clear path forward for future advancements.
When we started the Wellcome Leap program, it wasn’t clear exactly how or where quantum computing could meaningfully impact biology.
Shihan Sajeed, Program Director for Q4Bio
Q4Bio Validates Hybrid Quantum-Classical Pipelines for Health Applications
This success wasn’t simply about achieving a technical benchmark; the program depth of 10³, to 10⁴ demonstrated a scalable path toward future quantum advantage, a critical hurdle for the field. Rather than solely pursuing theoretical gains, Q4Bio established a clear understanding of quantum computing’s potential and limitations in healthcare, with teams delivering critical scientific contributions and creating hybrid quantum-classical pipelines. Wellcome Leap anticipates building on this progress with a follow-on initiative, aiming to further refine quantum-enabled solutions for biology and health applications as hardware capabilities continue to evolve.
Q4Bio was designed to create new solutions that would answer that question within real biological and hardware constraints.
Shihan Sajeed, Program Director for Q4Bio
